7 completed, 4 active not recruiting, 2 not yet recruiting, 1 approved for marketing. 10 Phase 2, 3 Phase 1, 2 Phase 3, 1 Phase 4.
Follow NS Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) NS-863 Low Dose, NS-863 High Dose, Placebo - Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Phase 2 | Not yet recruiting | NS Pharma, Inc. | 177 | 2026-07-01 | 2026-02-27 |
| Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) NS-863 Low Dose, NS-863 High Dose, NS-863 Placebo - Pulmonary Arterial Hypertension | Phase 2 | Not yet recruiting | NS Pharma, Inc. | 135 | 2026-07-01 | 2026-02-27 |
| NS-050/NCNP-03 in Boys With DMD (Meteor50) NS-050/NCNP-03, Placebo - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Active not recruiting | NS Pharma, Inc. | 20 | 2024-09-18 | 2026-06-16 |
| NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) NS-089/NCNP-02 - Duchenne Muscular Dystrophy, Exon 44 | Phase 2 | Active not recruiting | NS Pharma, Inc. | 20 | 2024-02-22 | 2026-09-15 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS-229, Placebo - Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome | Phase 2 | Active not recruiting | NS Pharma, Inc. | 45 | 2023-12-20 | 2026-05-26 |
| Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis NS-018, Best Available Therapy - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | NS Pharma, Inc. | 7 | 2023-01-31 | 2025-05-23 |
| Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53) Viltolarsen - Duchenne Muscular Dystrophy | Phase 2 | Completed | NS Pharma, Inc. | 20 | 2021-07-01 | 2024-08-20 |
| Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) Viltolarsen - Duchenne Muscular Dystrophy | Phase 4 | Active not recruiting | NS Pharma, Inc. | 9 | 2021-06-10 | 2022-10-19 |
| Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) Viltolarsen - Duchenne Muscular Dystrophy | Phase 3 | Unknown | NS Pharma, Inc. | 74 | 2021-04-13 | 2024-02-14 |
| Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) Viltolarsen, Placebo - Duchenne Muscular Dystrophy | Phase 3 | Completed | NS Pharma, Inc. | 77 | 2020-04-14 | 2024-12-11 |
| Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families Duchenne Muscular Dystrophy, Burden, Dependency | Completed | Jett Foundation, Inc. | 60 | 2018-09-20 | 2019-04-01 | |
| Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) NS-065/NCNP-01 - Duchenne Muscular Dystrophy | Phase 2 | Completed | NS Pharma, Inc. | 16 | 2017-07-06 | 2022-12-28 |
| Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) NS-065/NCNP-01, Placebo - Duchenne Muscular Dystrophy | Phase 2 | Completed | NS Pharma, Inc. | 16 | 2016-12-01 | 2021-12-07 |
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF NS-018 - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Completed | NS Pharma, Inc. | 77 | 2011-06-01 | 2022-03-09 |
| Study of NS-9 in Patients With Liver Metastases NS-9 [Poly I: Poly C] - Liver Neoplasms, Neoplasm Metastasis | Phase 1 | Completed | NS Pharma, Inc. | 20 | 2002-09-01 | 2005-11-11 |
| The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation viltolarsen - Muscular Dystrophy, Duchenne, DMD | Approved for marketing | NS Pharma, Inc. | 2020-08-18 |
Muscular Dystrophy, Duchenne (10) · Primary Myelofibrosis (2) · Bone Marrow Diseases (1) · Breast Neoplasms (1) · Churg-Strauss Syndrome (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hematologic Diseases (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1)
viltolarsen (5) · Poly I-C (1)
United States (12) · Canada (8) · Turkey (Türkiye) (6) · Italy (5) · South Korea (5) · Japan (4) · Spain (4) · United Kingdom (4) · Australia (3) · China (3) · New Zealand (3) · Russia (3) · Chile (2) · Germany (2) · Greece (2)
Paula R. Clemens, MD (2) · Christine McSherry, R.N. (1) · Srdan Verstovsek, M.D., Ph.D. (1)